# Pizarra — PT-pseudo_3477ea7065bd (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_3477ea7065bd
Task: 1

Encounter: Urology - outpatient on 08 Jan 2025.
Referrer: Dr. L. Smits (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 13.9 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.177 ng/mL²
  - PSA velocity: 1.41 ng/mL/yr
  - Prior PSA: 11.7 ng/mL
  - Prostate volume: 78.69 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.5224143 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 13.9 ng/mL. PI-RADS 4. PSAD 0.18. Prostate volume 79 mL. csPCa 0.52.

Vitals: weight 77 kg, height 186 cm, BMI 22.3, BP 119/82 mmHg, HR 70 bpm. Smoking: Ex-smoker (33 pack-yr, quit 2019).

Chief complaint: Persistent elevation in prostate-specific antigen values alongside newly acquired multiparametric magnetic resonance imaging results warrant clinical assessment.

History: At age 65, this retired butcher recently moved into his sister’s residence half a year ago. Initial investigation into an early 2023 prostate-specific antigen elevation revealed a continuous two-year ascent, culminating in a current value of 13.9 ng/mL. Voiding difficulties remain bothersome, registering an IPSS score of 22. Tobacco use ceased in 2019 after a cumulative exposure of 33 pack-years. Physical activity includes cycling roughly 20 kilometres twice weekly, with alcohol intake limited to four units per week. Medical background remains clear of comorbidities: none. Active medication: None. Past surgical history includes a radical prostatectomy completed six years prior and a routine knee arthroscopy five years back, alongside uncomplicated biannual dental visits. Mild vision loss is managed through large-print correspondence requests. Sleep patterns and weight remain stable. Following a divorce and his recent relocation, practical assistance is provided by his sister. Prior biopsy bucket: None.

Physical examination: DRE — consistency: smooth and firm; symmetry: balanced enlargement without discrete nodules or focal irregularities. Vital parameters remain stable at 119/82 mmHg with a regular cardiac rhythm of 70 beats per minute. Systemic survey reveals no abdominal masses or peripheral lymphadenopathy.

Patient info: retired butcher; Divorced; Recently relocated; lives with sister.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 4 units / week; exercise Cycling 2x/week, ~20 km; IPSS score: 22/35 (severe LUTS).

Recent other appointments: Dental — biannual check-up.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.76 +/- 0.17   (95% CI 0.37-0.98)

Where the uncertainty comes from:
  - aleatoric  dA = 0.14  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.08  (few labelled cases resemble this one)
  - 5.7 effective neighbours out of 10; 4 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'supports': A +/- dA does not cross 0.5, but A +/- 1.96*dA does. There is a direction, not a conclusion. Measured accuracy in this tier: 0.67. Treat it as a weighted vote, not as a decision.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=0.0, psa=13.9, age=65.0, psad=0.177, dre_ord=0.0, vol=78.69, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the PSA velocity (1.41 ng/mL/yr) and the specific trajectory of the PSA (prior 11.7 ng/mL to current 13.9 ng/mL), which suggests a rapid rise. It also missed the context of the PI-RADS 4 score in relation to the PSA density (0.177 ng/mL²), which is crucial for risk stratification.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests biopsy (0.76), but the patient has a prior biopsy status of "None". A prior negative biopsy would fundamentally change the question from "does he have cancer" to "is the current finding significant enough to warrant a repeat biopsy given the trajectory and imaging score." The wide error bar ($\pm 0.17$) suggests high uncertainty, which is amplified by the lack of dynamic data like the PSA trend.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details suspicious lesions or specific characteristics of the PI-RADS 4 area, it would refine the clinical suspicion.
  <document> PSA history (trend / velocity beyond the headline value) -> If the trend is highly aggressive, it would increase the urgency for intervention.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the LUTS or prior management that influences the decision threshold.
  <document> laboratory results (full panel) -> This panel might provide context on other markers that could modify the risk assessment.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_3477ea7065bd", "radiology_report": "Subject: Prostate mpMRI | Facility: Spaarne Gasthuis, Haarlem | Date: 05 Jan 2025\n\nClinical indication: Elevated PSA (13.9 ng/mL) and urology follow-up.\n\nFINDINGS:\nProstate volume: 78.69 mL. The gland demonstrates heterogeneous parenchymal architecture with moderate benign enlargement. A focal lesion is identified in the right peripheral zone at the mid-gland level, measuring approximately 12 x 10 mm. The lesion exhibits marked hypointensity on T2-weighted images, restricted diffusion on DWI with corresponding low ADC values, and early focal enhancement on dynamic contrast-enhanced sequences. No extraprostatic extension or seminal vesicle invasion is observed. Pelvic lymph nodes are unremarkable. No suspicious osseous lesions are seen.\n\nIMPRESSION:\nPI-RADS 4 lesion in the right mid-peripheral zone.\nPSAD: 0.177 ng/mL/mL.\ncsPCa predicted probability 0.5224143."}

  **psa_trend**
  {"case_id": "PT-pseudo_3477ea7065bd", "psa_trend": [{"date": "Jan 2023", "val": 2.9}, {"date": "Sep 2023", "val": 4.9}, {"date": "May 2024", "val": 8.2}, {"date": "Jan 2025", "val": 13.9}]}

  **previous_notes**
  {"case_id": "PT-pseudo_3477ea7065bd", "previous_notes": [{"date": "10 Sep 2024", "author": "Dr. L. Smits (GP)", "text": "Clinical review highlighted a steady upward trajectory in prostate-specific antigen levels, climbing from 10.1 ng/mL in September 2023 to 11.7 ng/mL at the most recent assessment. Significant lower urinary tract distress, quantified at an IPSS score of 22, necessitated the urology consultation and subsequent multiparametric imaging request. Standard laboratory screenings returned within normal limits for renal parameters and haematology."}]}

  **laboratory_results**
  {"case_id": "PT-pseudo_3477ea7065bd", "laboratory_results": [{"name": "PSA", "val": "13.9 ng/mL", "date": "30 Nov 2024", "flag": "H"}, {"name": "Free PSA", "val": "3.56 ng/mL", "date": "30 Nov 2024", "flag": ""}, {"name": "%Free PSA", "val": "26%", "date": "30 Nov 2024", "flag": ""}, {"name": "Haemoglobin", "val": "14.7 g/dL", "date": "30 Nov 2024", "flag": ""}, {"name": "WBC", "val": "5.6 x10^9/L", "date": "30 Nov 2024", "flag": ""}, {"name": "Platelets", "val": "279 x10^9/L", "date": "30 Nov 2024", "flag": ""}, {"name": "Creatinine", "val": "87 umol/L", "date": "30 Nov 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "30 Nov 2024", "flag": ""}, {"name": "Testosterone", "val": "18.6 nmol/L", "date": "30 Nov 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "98 U/L", "date": "30 Nov 2024", "flag": ""}, {"name": "LDH", "val": "210 U/L", "date": "30 Nov 2024", "flag": ""}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PI-RADS 4 lesion in the right mid-peripheral zone
  - PSA velocity of 1.41 ng/mL/yr (rapid rise)
  - PSA trajectory shows a significant rise from 11.7 ng/mL to 13.9 ng/mL over two years.
  - Focal lesion identified on MRI measuring 12 x 10 mm with restricted diffusion and early enhancement.

  AGAINST sampling this patient now:
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - DRE findings: smooth and firm; symmetry: balanced enlargement without discrete nodules or focal irregularities

WHERE THIS LEANS
  The retrieved evidence strongly supports the statistical prior by showing high-risk imaging (PI-RADS 4) combined with a concerning PSA trajectory and a focal lesion on MRI. This leans towards a strong recommendation for biopsy to further characterize the lesion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the convergence of high-risk imaging (PI-RADS 4 lesion) and concerning clinical data, specifically the PSA trajectory showing a significant rise from 11.7 ng/mL to 13.9 ng/mL over two years. The PI-RADS 4 finding, coupled with a focal lesion on MRI measuring 12 x 10 mm with restricted diffusion, strongly justifies further tissue characterization. The statistical prior was supported by the retrieved evidence indicating high-risk features warranting sampling.

Variables that carried weight: age=noted, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
